Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
Dysrhythmias I: Introduction01:15

Dysrhythmias I: Introduction

Dysrhythmias refers to abnormalities in the heart's rhythm. They result from disruptions in the heart's electrical conduction system, which includes the sinoatrial(SA)node, atrioventricular(AV) node, the bundle of His, bundle branches, and Purkinje fibers.Definition and PathophysiologyDysrhythmias result from disorders of impulse formation, impulse conduction, or both. The heart contains specialized cells in the sinoatrial node, atrioventricular node, and the bundle of His and Purkinje fibers...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Dysrhythmias VII: Nursing Management of Dysrhythmias01:25

Dysrhythmias VII: Nursing Management of Dysrhythmias

Nursing management of dysrhythmias involves the following:AssessmentSubjective Assessment:The initial step involves gathering patient-reported symptoms such as dizziness, palpitations, and chest discomfort. It is crucial to collect a detailed history, including previous heart conditions, current medication use, and lifestyle factors like caffeine and alcohol consumption.Objective Assessment:This involves observing clinical signs such as jugular venous distention, cool and pale skin, and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Trends in 1-year persistence and adherence among initiators of high-potency, weight loss-indicated glucagon-like peptide 1 receptor agonists.

Journal of managed care & specialty pharmacy·2026
Same author

AMCP real-world evidence standards: Overcoming barriers to using real-world evidence in US payer decision-making.

Journal of managed care & specialty pharmacy·2025
Same author

Emerging trends in pharmaceutical payment models: Perspectives on the 2024 AMCP Foundation Survey.

Journal of managed care & specialty pharmacy·2025
Same author

Emerging trends in pharmaceutical payment models: Perspectives on the 2024 AMCP Foundation Survey.

Journal of managed care & specialty pharmacy·2025
Same author

Real-world persistence and adherence to glucagon-like peptide-1 receptor agonists among obese commercially insured adults without diabetes.

Journal of managed care & specialty pharmacy·2024
Same author

Descriptive, real-world treatment patterns, resource use, and total cost of care among eculizumab- and ravulizumab-treated members with paroxysmal nocturnal hemoglobinuria.

Journal of managed care & specialty pharmacy·2023
Same journal

Integrated Network Pharmacology and Experimental Validation Approach to Systematically Elucidate the Cardioprotective Mechanisms of Shengmai Injection.

Cardiovascular therapeutics·2026
Same journal

Prasugrel: Reassessing Its Role in Contemporary Antiplatelet Therapy.

Cardiovascular therapeutics·2026
Same journal

Correction to "Association of Initial Laxative Strategy With Clinical Outcomes in Critically Ill Patients With Acute Myocardial Infarction: A Retrospective Cohort Study".

Cardiovascular therapeutics·2026
Same journal

Baseline Ejection Fraction as a Modifier of Beta-Blocker Therapeutic Effects in Post-Acute Coronary Syndrome Patients With Non-Reduced Ejection Fraction: A Systematic Review and Meta-Analysis.

Cardiovascular therapeutics·2026
Same journal

The Prognostic Value of Different Patterns of Neoatherosclerosis and Treatment Modality in Patients With Coronary In-Stent Restenosis.

Cardiovascular therapeutics·2026
Same journal

Lycorine Attenuates Cardiac Fibrosis Through the Regulation of PYK2 Expression and Activity.

Cardiovascular therapeutics·2026
See all related articles

Related Experiment Video

Updated: Jun 17, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Dronedarone: current evidence and future questions.

Jeremy A Schafer1, Nicole K Kjesbo, Patrick P Gleason

  • 1Prime Therapeutics LLC, Eagan, MN, USA. jschafer@primetherapeutics.com

Cardiovascular Therapeutics
|January 16, 2010
PubMed
Summary
This summary is machine-generated.

Dronedarone offers an option for managing atrial fibrillation (AF), but is not suitable for patients with recent heart failure. It shows improved tolerability over amiodarone but with less efficacy.

More Related Videos

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

Robotic Ablation of Atrial Fibrillation
11:21

Robotic Ablation of Atrial Fibrillation

Published on: May 29, 2015

Related Experiment Videos

Last Updated: Jun 17, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

Robotic Ablation of Atrial Fibrillation
11:21

Robotic Ablation of Atrial Fibrillation

Published on: May 29, 2015

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Atrial fibrillation (AF) is a common arrhythmia affecting millions.
  • Current guidelines recommend amiodarone for rhythm control in AF.
  • Dronedarone, an amiodarone derivative, is indicated for AF treatment.

Purpose of the Study:

  • To review dronedarone's Phase III clinical trials.
  • To discuss current and future questions regarding dronedarone use.

Main Methods:

  • Literature search of PubMed using "dronedarone".
  • Reviewed FDA documents and clinicaltrials.gov.
  • Analysis of five Phase III trials: ANDROMEDA, EURIDIS/ADONIS, ATHENA, ERATO, DIONYSIS.

Main Results:

  • EURIDIS/ADONIS and ATHENA trials showed reduced AF recurrence with dronedarone versus placebo.
  • ANDROMEDA trial terminated due to excess deaths in heart failure patients.
  • DIONYSIS trial indicated less efficacy but better tolerability for dronedarone compared to amiodarone.

Conclusions:

  • Dronedarone is an option for select AF patients, excluding those with recent decompensated heart failure or contraindications.
  • Dronedarone offers improved tolerability versus amiodarone at the cost of efficacy.
  • Further research is needed on long-term safety, heart failure use, and comparative effectiveness.